Fever Definition in B-Cell Lymphoma Patients on Therapy
In patients with B-cell lymphoma receiving therapy, fever is defined as a single oral temperature ≥38.3°C (101°F) or a temperature ≥38.0°C (100.4°F) sustained over 1 hour 1, 2.
Key Temperature Thresholds
The standard definition used across major guidelines for neutropenic cancer patients includes:
- Single measurement: ≥38.3°C (101°F) oral temperature
- Sustained measurement: ≥38.0°C (100.4°F) maintained for at least 1 hour
This definition applies specifically to patients with neutropenia (absolute neutrophil count <500 cells/mm³ or <1000 cells/mm³ with predicted decline to <500 cells/mm³) 3, 1.
Temperature Measurement Methods
Preferred methods (in order of reliability):
- Central temperature monitoring (pulmonary artery catheter thermistors, bladder catheters, esophageal probes) when devices are already in place 2
- Oral temperature for routine monitoring
- Rectal temperature (though generally avoided in neutropenic patients due to risk of mucosal injury and bacteremia)
Avoid: Axillary temperatures, tympanic membrane measurements, temporal artery thermometers, and chemical dot thermometers are discouraged as they may not accurately reflect core body temperature 1, 2.
Critical Clinical Context
These definitions are general criteria to identify patients requiring urgent empirical antibiotic therapy, not hard-and-fast rules 1. Clinical judgment remains essential—some patients may require antibiotics even without meeting these exact temperature criteria if they show signs of clinical deterioration, hypotension, or other concerning features during neutropenia.
Urgent Action Required
Any fever meeting these criteria in a neutropenic patient with B-cell lymphoma on therapy constitutes a medical emergency requiring:
- Empirical broad-spectrum antibiotics within 1-2 hours of presentation 1, 4
- Blood cultures and basic diagnostic workup before antibiotic initiation
- Immediate clinical assessment regardless of whether an infection source is identified
The majority of febrile neutropenic patients have no identifiable infection source or positive cultures, yet infection can progress rapidly, making prompt antibiotic initiation critical for reducing morbidity and mortality 1.